ScreenerHero

FATE Fate Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · fatetherapeutics.com
2.150USD-6.11%Mkt Cap: 257.61M $P/E: —

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen r…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap257.61M USD
Enterprise Value196.30M USD
Revenue (TTM)6.49M USD
Gross Profit-77.93M USD
Net Income (TTM)-136.31M USD
Revenue/Share0.05 USD
Last Price2.150 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees161
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.37
PEG—
EV/EBITDA-1.63
EV/Revenue30.24
P/S42.27
P/B1.74
EPS (TTM)-0.99
EPS (Forward)-0.97
52W Range
0.950053% of range3.230
52W High3.230 USD
52W Low0.9500 USD
Profitability
Gross Margin0.00%
Oper. Margin-1495.39%
EBITDA Margin0.00%
Profit Margin-2051.08%
ROE-65.79%
ROA-42.74%
Growth
Revenue Growth9.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-106.08M USD
CapEx (TTM)5.95M USD
FCF Margin-749.64%
FCF Yield-18.89%
Net Debt-78.09M USD
Net Debt/EBITDA0.65
Balance Sheet
Debt/Equity0.38
Current Ratio4.85
Quick Ratio4.75
Book Value/Sh1.31 USD
Cash/Share1.28 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.2 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)5.744 USD
Upside (mean)+167.2%
Target Range2.200 USD – 8.000 USD
2.200+167.2% to mean8.000
# Analysts9
Ownership
Shares Out.119.82M
Float105.48M
Insiders1.07%
Institutions69.04%
Short Interest
Short Ratio7.8d
Short % Float8.85%
Short % Out.7.83%
Shares Short9.39M
Short (prev mo.)8.51M
Technical
SMA 502.476 (-13.2%)
SMA 2001.859 (+15.7%)
Beta2.53
S&P 52W Chg16.45%
Avg Vol (30d)1.38M
Avg Vol (10d)1.57M
Technical Indicators
RSI (14)37.1
MACD-0.0576
MACD Signal-0.0428
MACD Hist.-0.0148
BB Upper2.583 USD
BB Middle2.382 USD
BB Lower2.181 USD
BB Width16.89%
ATR (14)0.1622 USD
Vol Ratio (20d)0.60x